Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Alivus Life Sciences, formerly Glenmark Life Sciences, manufactures active pharmaceutical ingredients with strength in select high-value chronic-therapy APIs across cardiovascular, CNS, diabetes and other categories. It supplies regulated and emerging markets and runs a growing CDMO stream, operating plants in Gujarat and Maharashtra. The company was acquired by the Nirma group from Glenmark Pharmaceuticals and subsequently renamed; revenue is driven by API volumes in its leadership molecules.
A leading Indian pure-play API maker with global leadership in several niche molecules.
Alivus Life Sciences Ltd. is a constituent of NIFTY MICROCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Alivus Life Sciences Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY24 (year ended 31 Mar 2024).
| Metric | FY24 | FY23 | FY22 |
|---|---|---|---|
| EPS (basic, ₹) | — | 38.11 | 35.63 |
| Return on equity | 20.2% | 21.8% | 20.4% |
| Return on capital employed | 25.7% | 27.3% | 27.7% |
| Operating margin | 27.2% | 27.8% | 27.2% |
| Net margin | 20.6% | 21.6% | 19.7% |
| EBITDA | ₹674 Cr | ₹642 Cr | ₹616 Cr |
| Free cash flow | ₹285 Cr | ₹143 Cr | ₹465 Cr |
| Interest coverage | 401.6 | 1097.3 | 20.7 |
| Current ratio | 4.37 | 3.67 | 4.60 |
Open the full income statement, balance sheet and cash flow for ALIVUS →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.